Glicklich D, Kapoian T, Mian H, Gilman J, Tellis V, Croizat H
Department of Medicine, Montefiore Medical Center of the Albert Einstein College of Medicine, Bronx, New York, USA.
Transplantation. 1999 Jul 15;68(1):62-6. doi: 10.1097/00007890-199907150-00012.
Angiotensin-converting enzyme inhibitors (ACEI) have become the treatment of choice for posttransplantation erythrocytosis (PTE). Yet the pathogenesis of PTE and the mechanisms of action of ACEI remain unclear. Therefore, we studied the dose response to erythropoietin (Ep), angiotensin II (AII), and the ACEI enalaprilat on the in vitro proliferation of erythroid progenitors in patients with PTE and in controls. We also evaluated ACE polymorphism in the two groups.
Twelve patients with PTE and 12 renal transplant patients without PTE were studied. Erythroid burst-forming units (BFU-E) were isolated from peripheral blood using standard methods. Ep sensitivity was determined for four patients with PTE and three control patients, using 0-3 U/ml Ep. AII dose response was studied in four patients with PTE and five control patients, using AII concentrations of 0-1000 nM. The effect of enalaprilat was studied in eight patients with PTE and eight control patients, using drug concentrations of 0-10 ng/ml. ACE gene insertion/deletion polymorphism was determined by polymerase chain reaction.
PTE patients showed a significant shift of the Ep response curve to the left compared with controls, with 50% maximal growth occurring at a lower Ep concentration (0.3 U/ml vs. 0.95 U/ml, P<0.025.) However, there was no difference in the number of BFU-E colonies between PTE patients and controls. AII added to the growth medium produced only minor stimulation in both groups. PTE patients showed significant inhibition of BFU-E growth with 10 ng/ml enalaprilat, but controls showed no inhibition of BFU-E growth with ACEI. There was no difference in ACE polymorphism between PTE and controls.
Our data suggest that PTE is associated with increased erythroid progenitor sensitivity to Ep. The effect of ACEI to decrease hematocrit in patients with PTE may be due to inhibition of red cell precursor growth.
血管紧张素转换酶抑制剂(ACEI)已成为移植后红细胞增多症(PTE)的首选治疗药物。然而,PTE的发病机制以及ACEI的作用机制仍不清楚。因此,我们研究了PTE患者和对照组中促红细胞生成素(Ep)、血管紧张素II(AII)以及ACEI依那普利拉对红系祖细胞体外增殖的剂量反应。我们还评估了两组患者的ACE基因多态性。
研究了12例PTE患者和12例无PTE的肾移植患者。采用标准方法从外周血中分离红系爆式集落形成单位(BFU-E)。对4例PTE患者和3例对照患者,使用0 - 3 U/ml的Ep测定Ep敏感性。对4例PTE患者和5例对照患者,使用0 - 1000 nM的AII浓度研究AII剂量反应。对8例PTE患者和8例对照患者,使用0 - 10 ng/ml的药物浓度研究依那普利拉的作用。通过聚合酶链反应测定ACE基因插入/缺失多态性。
与对照组相比,PTE患者的Ep反应曲线明显向左移动,最大生长的50%发生在较低的Ep浓度下(0.3 U/ml对0.95 U/ml,P<0.025)。然而,PTE患者和对照组之间的BFU-E集落数量没有差异。添加到生长培养基中的AII在两组中仅产生轻微刺激。PTE患者在使用10 ng/ml依那普利拉时BFU-E生长受到显著抑制,但对照组使用ACEI时BFU-E生长未受抑制。PTE患者和对照组之间的ACE基因多态性没有差异。
我们的数据表明,PTE与红系祖细胞对Ep的敏感性增加有关。ACEI降低PTE患者血细胞比容的作用可能是由于抑制了红细胞前体的生长。